The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis

Published:2023-10 Issue: Volume:71 Page:138-142
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Petrelli Fausto^ORCID,Dottorini Lorenzo^ORCID,Di Menna Giandomenico,Borgonovo Karen,Parati Maria Chiara,Rea Carmen Giusy,Ghilardi Mara,Ghidini Antonio^ORCID,Luciani Andrea

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference37 articles.

1. Breast cancer statistics, 2022;Giaquinto;Ca - Cancer J Clin,2022

2. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews;Page;Syst Rev,2021

3. RoB 2: a revised tool for assessing risk of bias in randomised trials;Sterne;BMJ,2019

4. Measuring inconsistency in meta-analyses;Higgins;BMJ,2003

5. Meta-analysis in clinical trials;DerSimonian;Contr Clin Trials,1986

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review;Targeted Oncology;2024-03-28

2. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study;2024

3. Fundamental Considerations of Targeted Drug Therapies for Breast Cancer;Future Pharmacology;2023-10-08

4. An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials;Biomolecules;2023-09-20